Vicore Pharma Holding AB
STO:VICO
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
6.9665
23.3
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one VICO stock under the Base Case scenario is 7.71 SEK. Compared to the current market price of 7.12 SEK, Vicore Pharma Holding AB is Undervalued by 8%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Vicore Pharma Holding AB
Run backtest to discover the historical profit from buying and selling VICO based on its intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Price Target |
Loading
|
Revenue Forecast |
|
Operating Income Forecast |
|
Earnings Forecast |
|
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Vicore Pharma Holding AB
Balance Sheet Decomposition
Vicore Pharma Holding AB
Current Assets | 478.2m |
Cash & Short-Term Investments | 466.4m |
Receivables | 1.6m |
Other Current Assets | 10.1m |
Non-Current Assets | 565k |
PP&E | 10k |
Intangibles | 555k |
Current Liabilities | 39.9m |
Accounts Payable | 18.2m |
Accrued Liabilities | 17.1m |
Other Current Liabilities | 4.7m |
Non-Current Liabilities | 3.8m |
Other Non-Current Liabilities | 3.8m |
Earnings Waterfall
Vicore Pharma Holding AB
Revenue
|
104.2m
SEK
|
Operating Expenses
|
-329.8m
SEK
|
Operating Income
|
-225.6m
SEK
|
Other Expenses
|
25.5m
SEK
|
Net Income
|
-200.1m
SEK
|
Free Cash Flow Analysis
Vicore Pharma Holding AB
SEK | |
Free Cash Flow | SEK |
VICO Profitability Score
Profitability Due Diligence
Vicore Pharma Holding AB's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
Score
Vicore Pharma Holding AB's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
VICO Solvency Score
Solvency Due Diligence
Vicore Pharma Holding AB's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Score
Vicore Pharma Holding AB's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VICO Price Targets Summary
Vicore Pharma Holding AB
According to Wall Street analysts, the average 1-year price target for VICO is 51 SEK with a low forecast of 40.4 SEK and a high forecast of 73.5 SEK.
Shareholder Yield
Current shareholder yield for VICO is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
VICO Price
Vicore Pharma Holding AB
Average Annual Return | 13.84% |
Standard Deviation of Annual Returns | 68.76% |
Max Drawdown | -81% |
Market Capitalization | 795.5m SEK |
Shares Outstanding | 111 734 000 |
Percentage of Shares Shorted |
N/A
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2015-12-10. The firm's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The firm is a wholly owned subsidiary of Mintage Scientific AB.
Contact
IPO
Employees
Officers
The intrinsic value of one VICO stock under the Base Case scenario is 7.71 SEK.
Compared to the current market price of 7.12 SEK, Vicore Pharma Holding AB is Undervalued by 8%.